Fluorofentanyl and novel synthetic opioids in accidental overdose deaths.

Abstract

One of the quickest-growing subclasses of novel psychoactive substances is novel synthetic opioids (NSOs), which are categorized as fentanyl analogs (fentalogs) or nonfentanyl opioids that bind to the mu-opioid receptor. Increased detections of NSOs have been observed in the USA. However, limited information on their prevalence outside of the East Coast is available. This study details the prevalence of NSOs, specifically fluorofentanyl, in the biological and drug paraphernalia specimens of accidental overdose deaths in San Francisco in 2022. A recently developed and validated liquid chromatography with tandem mass spectrometry method was utilized for the analysis of >250 NSOs. Out of the 649 accidental overdose deaths in 2022, 617 cases were available for blood analysis, with at least 1 NSO detected in 48 cases (7.8%). Fentalogs were detected in all 48 cases, with fluorofentanyl being detected in 40 cases. In postmortem femoral blood, estimated concentrations of fluorofentanyl ranged from 0.1 to 8.9 ng/mL, and 0.05 to 85 ng/mL in urine. Polysubstance use with NSO was seen with fentanyl (89.6%), methamphetamine (70.8%), cocaine (33.3%), and heroin (18.8%). NSOs, mainly fluorofentanyl, were observed in matched drug paraphernalia. This report documents the migration of fluorofentanyl to the West Coast, specifically California.